Spinal injuries therapy (NEUROREG) - Histocell

Drug Profile

Spinal injuries therapy (NEUROREG) - Histocell

Latest Information Update: 15 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Histocell
  • Developer Histocell; Noray Bioinformatics
  • Class Antihyperglycaemics; Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Spinal cord injuries

Most Recent Events

  • 15 Jul 2016 Preclinical trials in Spinal cord injuries (Diagnosis) in Spain (Parenteral)
  • 15 Jul 2016 Preclinical trials in Spinal cord injuries in Spain (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top